Sanofi Consumer Healthcare India Limited (SANOFICONR) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
28 Apr, 2026Executive summary
Unaudited financial results for the quarter ended March 31, 2026, were approved by the Board on April 28, 2026.
The statutory auditors issued a limited review report with an unmodified conclusion.
Financial highlights
Revenue from operations for Q1 2026 was ₹2,292 million, up from ₹1,726 million in Q1 2025.
Profit before tax for Q1 2026 was ₹907 million, compared to ₹668 million in Q1 2025.
Net profit for Q1 2026 stood at ₹678 million, up from ₹500 million in Q1 2025.
Basic and diluted EPS for Q1 2026 was ₹29.44, compared to ₹21.69 in Q1 2025.
Outlook and guidance
Domestic sales grew by 15.5% year-over-year, aided by product relaunches.
Export sales increased by 144.4% year-over-year on a lower base.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Sanofi Consumer Healthcare India Limited
- Double-digit growth achieved through brand leadership, digital focus, and operational excellence.SANOFICONR
Investor presentation24 Mar 2026 - FY25 net profit rose to ₹2,401 million on revenue of ₹8,045 million; ₹75/share dividend proposed.SANOFICONRQ4 202525 Feb 2026
- Half-year net profit was ₹917 million, with results shaped by demerger and product recalls.SANOFICONRQ2 202418 Feb 2026
- Q3 2024 revenue reached ₹1,599 million, with net profit at ₹450 million amid product recalls.SANOFICONRQ3 202418 Feb 2026
- FY 2024 net profit reached ₹1,810 million, with strong core portfolio performance and a ₹55 dividend.SANOFICONRQ4 202418 Feb 2026
- Q1 2025 net profit fell to ₹500 million amid product recalls; Depura Adult relaunched.SANOFICONRQ1 202518 Feb 2026
- Q2 2025 revenue up 28% YoY and profit after tax up 21%, led by launches and export growth.SANOFICONRQ2 202518 Feb 2026
- Q3 2025 revenue up 46% and net profit up 40% year-over-year, with all recalled products relaunched.SANOFICONRQ3 202518 Feb 2026